European Union

European UCaaS Market Growth Opportunities Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 6, 2021
Mobile, Wireless, Technology, Telecommunications, Cloud, Adoption, Travel, Technology, Workforce, European Union, Awareness, CAPEX, Solution, Unified communications as a service, Microsoft, Eurozone, COVID-19, Sochos, GDP, Investment, 365, Union, Super Mario, Employment, Digital technology, Commerce, Growth, Retail, Tourism, Video game console

The "Growth Opportunities in the European UCaaS Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Growth Opportunities in the European UCaaS Market" report has been added to ResearchAndMarkets.com's offering.
  • This study provides an in-depth analysis of trends, growth factors and growth opportunities in the European UCaaS market.
  • Market participants can leverage the findings of this study to build sustainable business models and growth strategies.
  • UCaaS providers will pursue untapped opportunities among new customer segments, including SOHOs and micro-businesses, frontline workers, mid-market and large enterprises.

Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV

Retrieved on: 
Monday, December 6, 2021
Patient, Regulation of tobacco by the U.S. Food and Drug Administration, SEDAR, Mission statement, Nausea, Taime Downe, European Union, Company, Viral load, Rash, Forward-looking statement, Vitamin, Pharmacokinetics, IV, TSX, Food, Immune reconstitution inflammatory syndrome, COVID-19, Breast milk, Physician, GLOBE, Diarrhea, Dizziness, Infection, EDGAR, Therapy, Subtypes of HIV, Union, FDA, Immune system, HIV-1, NASDAQ, HIV, MDR, Pharmaceutical industry, Vaccine

The IV Push Trogarzo program continues the Companys commitment to improving the lives and treatment outcomes for patients living with HIV.

Key Points: 
  • The IV Push Trogarzo program continues the Companys commitment to improving the lives and treatment outcomes for patients living with HIV.
  • The FDA submission is the next step in the advancement of Theratechnologies Trogarzo IV Push program.
  • Trogarzo IV Push, a more convenient form of administration, can be infused within 30 seconds without dilution compared to the 15-minute infusion time of the original IV Infusion.
  • Secondary endpoints were also achieved confirming no difference in HIV-1 viral load due to the change from IV Infusion to IV Push.

Merck Canada Announces Expansion of Manufacturing for Molnupiravir, an Investigational Oral Antiviral Medicine for the Treatment of COVID-19

Retrieved on: 
Monday, December 6, 2021
MSD, Patient, Security (finance), News, Supply, Coronavirus, Annual report, European Union, Private Securities Litigation Reform Act, Economic development, Population, NYSE, Partnership, Medicine, Cancer, SEC, The Honourable, U.S. Securities and Exchange Commission, Therapy, Vaccine, COVID-19, Animal, Thermo Fisher Scientific, Indigenous self-government in Canada, Investment, Research, United Kingdom, Patent, Government, Union, Infection, Merck & Co., YouTube, Ministry of Economic Development, Job Creation and Trade, MRK, Life, HIV, Pharmaceutical industry

This agreement is part of Merck's commitment to make this investigational medicine widely available globally, if approved for use by regulatory agencies.

Key Points: 
  • This agreement is part of Merck's commitment to make this investigational medicine widely available globally, if approved for use by regulatory agencies.
  • Merck also announced on December 3, 2021, that it has entered into a Supply Agreement with the Government of Canada for molnupiravir.
  • Through this agreement, the Government of Canada has secured access to 500,000 patient courses, with options for up to 500,000 morein 2022.
  • "We are honoured to be partnering with the federal and provincial governments in support of our country's preparedness against COVID-19.

ExxonMobil Plans For Net Zero Emissions in Permian Basin Operations by 2030

Retrieved on: 
Monday, December 6, 2021
Oil, Gas, Alternative Energy, Energy, Environment, Other Energy, Permian, Zero, API, Carbon, Wind, Technology, XTO, Industry, Annual report, European Union, Achievement, Exxon, Economic development, American Petroleum Institute, Energy factor, ExxonMobil, Hydrogen, Investor, Program, COVID-19, IPIECA, Twitter, View, Corporation, Research, Methane, MIQ, LinkedIn, Multimedia, Population growth, Mobil, Natural gas, Oil, Petroleum, Renewable energy

ExxonMobil said today it plans to achieve net zero greenhouse gas emissions from operated assets in the U.S. Permian Basin by 2030, accelerating and expanding its emission-reduction plans for unconventional operations in New Mexico and Texas.

Key Points: 
  • ExxonMobil said today it plans to achieve net zero greenhouse gas emissions from operated assets in the U.S. Permian Basin by 2030, accelerating and expanding its emission-reduction plans for unconventional operations in New Mexico and Texas.
  • View the full release here: https://www.businesswire.com/news/home/20211206005252/en/
    ExxonMobil currently operates ground-based monitors around the Permian Basin and plans to increase deployment to enhance methane monitoring as part of the company's plans to achieve net zero greenhouse gas emissions.
  • (Photo: Business Wire)
    Our groundbreaking plans to reach net zero for Permian Basin operations further demonstrate our commitment and support of societys ambitions for a lower-emissions future, said Darren Woods, chairman and chief executive officer.
  • By year-end 2021, ExxonMobil anticipates reduced flaring volumes across its Permian Basin operations by more than 75% compared to 2019.

Evrysdi® Distinguished by Two Prestigious Awards for Outstanding Innovation in Drug Discovery

Retrieved on: 
Monday, December 6, 2021
Research, Patient, Genentech, Infant, Pharmacology, Movement, Neuromuscular disease, Technology, British Pharmacological Society, Time, SMN2, European Union, SMN, Drug discovery, Mouth, Invention, Central nervous system, Federation of European Pharmacological Societies, Society, Twitter, Mutation, SMN1, Roche, Muscle weakness, SMA, RNA, Instagram, PTC Therapeutics, Union, Mortality, Clinical Medicine & Research, Scientist of the Year Award, Hoffmann-La Roche, Medicine, LinkedIn, Therapy, PTC, NASDAQ, Pharmaceutical industry, Fine chemical

The British Pharmacological Society has chosen Evrysdi as the 2022 Drug Discovery of the Year award.

Key Points: 
  • The British Pharmacological Society has chosen Evrysdi as the 2022 Drug Discovery of the Year award.
  • In addition, Evrysdi was awarded the 2021 Drug Discovery Prize by the Society for Medicines Research.
  • Evrysdi was selected from a list of 150 innovative medicines for the British Pharmacological Society's Drug Discovery of the Year award.
  • It recognizes outstanding contributions, achievements, and inventions in the world of drug discovery and development.

DGAP-News: Compleo Charging Solutions AG: Compleo's capital increase with subscription rights meets with positive response

Retrieved on: 
Monday, December 6, 2021
Article, Sale, Securities Act of 1933, European Union, Forward-looking statement, Company, Judgement of the German Federal Court of Justice on Google's autocomplete function, Finance, News, DGAP, European, Financial Services and Markets Act 2000, Person, Prospectus, Financial services, Urban economics, European Parliament, Publication, Relevance (Person of Interest), United Kingdom, Council, European Economic Area, European Union (Withdrawal) Act 2018, Joint, Physikalisch-Technische Bundesanstalt, Security (finance)

This release constitutes neither an offer to sell nor a solicitation to buy shares of the Company.

Key Points: 
  • This release constitutes neither an offer to sell nor a solicitation to buy shares of the Company.
  • An investment decision regarding the new shares of the Company should only be made on the basis of this securities prospectus.
  • The securities prospectus is available on the website of the Company (www.compleo-cs.com) under the " Investor Relations - Publications" section.
  • Forward-looking statements are based on the current views, expectations, assumptions and information of the management of the Company.

MarketAxess Announces Monthly Volume Statistics for November 2021

Retrieved on: 
Monday, December 6, 2021
Security (finance), Government, Adoption, Technology, Industry, European Union, Company, MarketAxess, Solution, U.S. Securities and Exchange Commission, United States Department of the Treasury, COVID-19, TRACE, Intellectual property, Nasdaq, GLOBE, Marketing, Union, Privacy, Failure, Animal

Record monthly portfolio trading volume in November; quarter-to-date portfolio trading reached $10.3 billion, exceeding the full third quarter of $8.9 billion.

Key Points: 
  • Record monthly portfolio trading volume in November; quarter-to-date portfolio trading reached $10.3 billion, exceeding the full third quarter of $8.9 billion.
  • U.S. Treasury bond volume of $432.7 billion, up 55% year-over-year; further adoption of the all-to-all Click-to-Trade protocol drove record investor client volume.
  • Emerging markets trading volume up 14% year-over-year in November; November 2021 year-to-date EM trading volume already 7% higher than full year 2020.
  • MarketAxess municipal bond volume grew 86% year-over-year to $2.2 billion; MuniBrokers platform volume of $6.5 billion.

CryoMass Technologies Releases Progress Report

Retrieved on: 
Monday, December 6, 2021
Humidity, Sale, Risk, QB, Technology, Industry, European Union, Cannabis, Temperature, Company, Soil, Private Securities Litigation Reform Act, Daou Technology Inc., European Union Intellectual Property Office, Pesticide, Health, SEC, Telephone, Wax, Plant, Oil, Substance-related disorder, Tax, Oxygen, CRYM, Patent, Collection, OTC, Trichome, Intention, Engineering, Element, 3D printing, Retail, Drug, Natural gas, Security (finance)

DENVER, Dec. 6, 2021 /PRNewswire/ --CryoMass Technologies Inc. (the "Company") reports as follows: We've been busy, and we're getting busier.

Key Points: 
  • DENVER, Dec. 6, 2021 /PRNewswire/ --CryoMass Technologies Inc. (the "Company") reports as follows: We've been busy, and we're getting busier.
  • The three-dimensional advantage achievable with the CryoMass system can as much as double a crop's wholesale value.
  • In connection with the financing, 1,010,000 shares and 760,000 shares of CryoMass Technologies common stock were purchased by CEO Christian Nol and Chairman of the Board Delon Human, respectively.
  • The common stock of CryoMass Technologies Inc. trades on the OTC QB market under the symbol CRYM.

Balsamic Vinegar of Modena Celebrates Winners of Annual Recipe Contest In Partnership With the Culinary Institute of America

Retrieved on: 
Monday, December 6, 2021
Consortium, Safety, European Union, Partnership, Awareness, Balsamic vinegar of Modena, Student, Balsamic vinegar, Originality, The Culinary Institute of America, European Commission, CIA, REA, Culinary Institute, Union, Perfume

NEW YORK, Dec. 6, 2021 /PRNewswire/ -- The Consortium of Balsamic Vinegar of Modena has celebrated the winners of their annual "Balsamic Vinegar of Modena Recipe Contest'', which challenged students from the Culinary Institute of America (CIA) to demonstrate innovative usage of the iconic European product in their recipes.

Key Points: 
  • NEW YORK, Dec. 6, 2021 /PRNewswire/ -- The Consortium of Balsamic Vinegar of Modena has celebrated the winners of their annual "Balsamic Vinegar of Modena Recipe Contest'', which challenged students from the Culinary Institute of America (CIA) to demonstrate innovative usage of the iconic European product in their recipes.
  • Students enrolled at the Culinary Institute of America's Hyde Park with a major in culinary and pastry arts were challenged tocreate a video offering an original application of Balsamic Vinegar of Modena PGI.
  • Entries in the juried competition were reviewed by representatives from the Culinary Institute of America and the Consorzio Tutela Aceto Balsamico di Modena (Balsamic Vinegar of Modena Consortium).
  • The Balsamic Vinegar of Modena Recipe Contest in partnership with the Culinary Institute of America is part of the project "Balsamic Vinegar of Modena, the Original", focused on the US market and financed by the European Union, to promote the added value of the Balsamic Vinegar of Modena, in terms of authenticity, safety, traceability, and labelling guaranteed by the European trademark protection.

MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study

Retrieved on: 
Monday, December 6, 2021
Patient, Burn, Government, Trial of the century, Review, Safety, Regeneration, Phrase, Face, Company, Debridement, Mouth ulcer, DFU, European Union, Inflammation, Contract, Incidence, Annual report, BARDA, COVID-19, Pain, Bromelain (pharmacology), Particle-size distribution, Research, Form 20-F, GLOBE, EMA, Granulation tissue, Wound healing, Development, IDMC, Union, FDA, Growth, Perseverance, Ulcer, VLU, Quality of life, Pharmaceutical industry, Medical device, Hospital

Phase 2 adaptive design clinical study evaluating the safety and efficacy of EscharEx in debridement of venous leg ulcers (VLUs) compared to gel vehicle (placebo control) and non-surgical standard-of-care (either enzymatic or autolytic debridement).

Key Points: 
  • Phase 2 adaptive design clinical study evaluating the safety and efficacy of EscharEx in debridement of venous leg ulcers (VLUs) compared to gel vehicle (placebo control) and non-surgical standard-of-care (either enzymatic or autolytic debridement).
  • We look forward to sharing topline data from this study in the first quarter of 2022.
  • The study is a multicenter, prospective, randomized, placebo-controlled, adaptive design study, evaluating the safety and efficacy of EscharEx in debridement of VLUs.
  • EscharEx is an investigational product and currently in a U.S. phase 2 adaptive design study.